Cullinan Oncology LLC (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for autoimmune diseases and cancer. The company is advancing several drug candidates, including CLN-978, a CD19xCD3 bispecific T cell engager in Phase 1 trials for autoimmune diseases; velinotamig, a BCMAxCD3 bispecific T cell candidate also in Phase 1 studies for autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in Phase 1 trials for relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. It is also developing zipalertinib, an oral small-molecule EGFR inhibitor being studied in the Phase 2b portion of the REZILIENT1 trial for EGFR ex20ins non-small cell lung cancer. Cullinan Therapeutics has collaboration and license agreements with Chongqing Genrix Biopharmaceutical, Taiho Pharmaceutical, and Adimab. The company, formerly known as Cullinan Oncology, Inc., was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.